ClinicalTrials.gg
CompletedNCT00568295Updated Aug 22, 2011

A Four-Week Study Comparing Acetaminophen Extended Release and Rofecoxib in the Treatment of Osteoarthritis of the Knee

A Phase 3 interventional study of acetaminophen and Rofecoxib in Osteoarthritis of the Knee, sponsored by Johnson & Johnson Consumer and Personal Products Worldwide. Completed. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2011-08-22.

Sponsored by Johnson & Johnson Consumer and Personal Products Worldwide (formerly part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
403
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 11 studies testing acetaminophen in Osteoarthritis, Knee — none open to participants now, none under way, none of them phase 3. Acetaminophen · Osteoarthritis, Knee.

Enrollment
4th of 11
403 · median 300
Started
1999
the only one that year
Phase 3
7 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
4 of 11
Johnson & Johnson Consumer and Personal Products Worldwide

Among the 11 studies testing acetaminophen in Osteoarthritis, Knee, this one is the 4th largest by enrollment, is the only one that started in 1999, is one of 7 in phase 3, and was the 5th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

None of the 11 studies testing acetaminophen in Osteoarthritis, Knee is open now. The open studies under Osteoarthritis, Knee, anywhere →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 385 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 114 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing acetaminophen in Osteoarthritis, Knee as a file.
02

Study summary

To compare acetaminophen (Tylenol) with rofecoxib (Viox) for the treatment of Osteoarthritis of the Knee

Read the detailed description

An initial screening visit was performed in order to assess subject medical history and the potential eligibility of subjects. Following the initial screening visit, all potential subjects underwent a washout period from their usual arthritis medication and returned to the study center for a baseline visit to verify their eligibility.

At the completion of the baseline visit, all eligible subjects were randomly assigned to a treatment group and instructed on the dosing regimen for their assigned study medication.

Subjects returned to the study center for follow-up visits after Week 1 and Week 2 of treatment and a final visit after Week 4 of treatment or upon discontinuation from the study.

03

Conditions studied

  • Osteoarthritis of the Knee
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptomatic idiopathic osteoarthritis of the knee for a minimum of six months duration requiring treatment with either an analgesic or anti-inflammatory agent on a regular basis (greater than or equal to three days/week) for at least three months.
  • A history of osteoarthritis of the knee characterized by pain of at least a moderate intensity.
  • Demonstrated radiographic evidence of mild to moderate osteoarthritis based on the Kellgren and Lawrence radiographic entry criteria of grade 2 or 3 osteoarthritis.
  • Subjects' physical ability was to be either American College of Rheumatology (ACR) Function Class I or II
  • At the baseline visit, subjects must have reported a maximum pain intensity experienced over the previous 24 hours of at least moderate on a five-point scale of none(0), mild(1), moderate(2), moderately severe(3), or severe(4) in order to be enrolled in the study.

Exclusion criteria

Exclusion Criteria:

  • Medical history, physical examinations, or radiographs suggestive of other types of arthritis, pseudogout, collagen vascular disease or fibromyalgia.
  • Medical or psychiatric conditions that may influence absorption, metabolism, or excretion of the study medications or interfere with interpretation of adverse reactions to the study drug.
  • History of allergy, sensitivity, or non-response to acetaminophen, rofecoxib, or drugs classified as NSAIDs including aspirin.
  • Use of concomitant medications that might interfere with study drug assessments, including intra-articular .
  • Signs of active knee inflammation, morning stiffness of greater than 30 minutes duration.
  • Rheumatoid factor quantitative value greater than or equal to 40 IU/mL or a Westergren erythrocyte sedimentation rate greater than or equal to 40 mm/hour.
  • ACR functional class III or IV, or unable to walk without assistive devices.
  • Pregnancy, lactation, or expect to become pregnant within one month of study completion.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
403 participants (actual)

Study arms

  • Experimental
    Acetaminophen

    Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP

    Drug: acetaminophen

  • Active comparator
    Refecoxib 12.5 mg

    Rofecoxib: Capsules 12.5 mg, oral, C-904-1A

    Drug: Rofecoxib

  • Active comparator
    Rofecoxib 12.5 x 2

    Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A

    Drug: Rofecoxib

Interventions

  • Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.

    Also known as: Tylenol

  • Rofecoxib: Capsules 12.5 mg, oral, C-904-1A - - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.

    Also known as: Viox

  • Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.

    Also known as: Viox

06

What researchers measure

Primary outcomes

  1. Change from Baseline in the Western Ontario and McMaster Universities (WOMAC) pain subscale score at week 4 in the per protocol study population.

    Time frame: Four Weeks

Secondary outcomes

  1. Change from Baseline in the WOMAC pain subscale score

    Time frame: Weeks 1 and 2

  2. Change from baseline in the WOMAC stiffness and physical function subscale scores

    Time frame: Weeks 1, 2 and 4

  3. Investigator's impression of therapeutic response

    Time frame: Weeks 1, 2, and 4

  4. Subject's assessment of medication as an analgesic for the study knee joint

    Time frame: Weeks 1, 2, and 4

  5. Daily pain intensity differences from baseline

    Time frame: Week 1

  6. Investigator's global impression of therapeutic response

    Time frame: Week 4

  7. Subject's overall impression of the study medication

    Time frame: Week 4

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 1999, a primary completion of Oct 2000 and a completion of Oct 2000. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2007
First posted
Dec 6, 2007
Start
Oct 1999
Primary completionActual
Oct 2000
CompletionActual
Oct 2000
Last update
Aug 22, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00568295
Responsible party
Sponsor
First posted
Dec 6, 2007
Start date
Oct 1999
Primary completion
Oct 2000
Completion
Oct 2000
Last update
Aug 22, 2011

Study contacts

Edwin Kuffner, MD
study director · McNeil Consumer Healthcare USA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion